(Updated - May 18, 2020 10:00 AM EDT)

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and raised his price target on Moderna (NASDAQ: MRNA) to $105.00 (from $63.00) following positive COVID vaccine data.

The price target is a new 'Street High'.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $66.69 yesterday.